$ZYME

Zymeworks Inc

  • NEW YORK STOCK EXCHANGE INC.
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$6.04 -

Extented Hours

VOLUME

1,596,346

DAY RANGE

5.23 - 5.66

52 WEEK

4.56 - 38.63

Join Discuss about ZYME with like-minded investors

KC
@KCj #StockTraders.NET
recently

Well overall red day for me again. Lost on several scalp/reversion trades around the open (as trying to learn from the TrueTrader room). Made back a little on $ZYME fade and $RDBX trades from my morning focus list. Learning day.

81 Replies 14 πŸ‘ 14 πŸ”₯

KC
@KCj #StockTraders.NET
recently

watching $ZYME under 6.30, watching for pops on $RDBX, $RVSN, $INVZ

87 Replies 12 πŸ‘ 11 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

eyeing $RDBX as per plan > @soheil.n said: watchlist: $INVZ: macro clear out over 5.3-5.5s $ZYME: (macro clear out is likely or at least push towards 8s...6.7 will need to base for that move) $RDBX: no borrows, looking for a break over 7.5 for a push towards 8.5 potential new ones in the morning

49 Replies 7 πŸ‘ 9 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

well nothing new to add this morning to the list...will be a quiet one unless something shows up later in the morning/afternoon > @soheil.n said: watchlist: $INVZ: macro clear out over 5.3-5.5s $ZYME: (macro clear out is likely or at least push towards 8s...6.7 will need to base for that move) $RDBX: no borrows, looking for a break over 7.5 for a push towards 8.5 potential new ones in the morning

106 Replies 6 πŸ‘ 15 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

watchlist: $INVZ: macro clear out over 5.3-5.5s $ZYME: (macro clear out is likely or at least push towards 8s...6.7 will need to base for that move) $RDBX: no borrows, looking for a break over 7.5 for a push towards 8.5 potential new ones in the morning

112 Replies 10 πŸ‘ 12 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

ss 7 avg, will cover into low 6.8s > @soheil.n said: big move on $ZYME as well

113 Replies 14 πŸ‘ 13 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

big move on $ZYME as well

74 Replies 14 πŸ‘ 8 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

watchlist: $INVZ, $ZYME, $APRN, $TDOC

91 Replies 8 πŸ‘ 7 πŸ”₯

BR
@brAli #StockTraders.NET
recently

zyme too salow

61 Replies 12 πŸ‘ 14 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$ZYME nice bounce

137 Replies 13 πŸ‘ 11 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

quite the push on $ZYME ...half size at 6.65...got too comfortable to place a stop at 6.8 > @soheil.n said: good rejection at the VPOC...want to see 6.7s top out

124 Replies 13 πŸ‘ 8 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

good rejection at the VPOC...want to see 6.7s top out > @soheil.n said: started ss on $ZYME avg 6.65

51 Replies 13 πŸ‘ 6 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

started ss on $ZYME avg 6.65

130 Replies 7 πŸ‘ 13 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

$ZYME - looking for 6.5 blow off

99 Replies 9 πŸ‘ 9 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$ZYME up on a buyout offer for $10.50 per share

138 Replies 6 πŸ‘ 13 πŸ”₯

profile
@dros #droscrew
recently

976.7k $ZYME @ 25

100 Replies 9 πŸ‘ 8 πŸ”₯

profile
@dros #droscrew
recently

RECAP 6/31 Chatter: $DBX + AMZN partnership $COTY + Kylie $SNAP + AMZN app $ZYME + Sale $ZNGA + chatter

98 Replies 15 πŸ‘ 15 πŸ”₯

profile
@viking #StockTraders.NET
recently

$ZYME Biopharmaceutical company Zymeworks Inc. (NYSE: ZYME) has received a takeover approach and is working with an investment bank to field other potential interest, according to a source. The initial bid for Zymeworks was said to be around $50 per share

87 Replies 8 πŸ‘ 10 πŸ”₯

profile
@viking #StockTraders.NET
recently

took some $ZYME here 37.30s

96 Replies 13 πŸ‘ 15 πŸ”₯

profile
@dros #droscrew
recently

+Initiations 2/8: $AAPL $AFRM $ALDX $BCEL $BTRS $ELDN $HIMS $HSIC $MIRM $MSGM $POSH $SRAX $TFFP $VSEC $WOOF $ZYME . -Initiations 2/8: $OMP

53 Replies 14 πŸ‘ 11 πŸ”₯

profile
@dros #droscrew
recently

Upgrades 1/29: $ADP $ADS $BA $CPRI $CTSH $EGBN $ENTA $FVCB $HYRE $ICHR $JACK $LXRX $MBCN $MEOH $MSI $NICE $OBNK $ONEM $PHM $RIDE $SLF $SLM $SR $UCTT $WDC $XONE $ZYME

142 Replies 6 πŸ‘ 7 πŸ”₯

profile
@Snowcow #droscrew
recently

i think that zyme one

82 Replies 11 πŸ‘ 10 πŸ”₯

profile
@dros #droscrew
recently

$ZYME 16OCT20 $40 Cs // 1.1k+ trading vs 297 OI

55 Replies 11 πŸ‘ 9 πŸ”₯

profile
@HeyShoe #droscrew
recently

big Zyme move

133 Replies 13 πŸ‘ 10 πŸ”₯

profile
@dros #droscrew
recently

this ZYME is a nice bet

77 Replies 11 πŸ‘ 12 πŸ”₯

profile
@dros #droscrew
recently

$ZYME 16OCT20 $40 Cs // 1.1k+ trading vs 297 OI

90 Replies 9 πŸ‘ 12 πŸ”₯

profile
@CarlosH-carvan #ivtrades
recently

@Marcosx watch this too $ZYME

147 Replies 8 πŸ‘ 7 πŸ”₯

profile
@ivtrades-Chris #ivtrades
recently

$ZYME some spreads going off there

142 Replies 14 πŸ‘ 11 πŸ”₯

profile
@HeyShoe #droscrew
recently

$ZYME has been dragged down

52 Replies 7 πŸ‘ 12 πŸ”₯

profile
@RedSunCap #ivtrades
recently

cutting ZYME for 50% loss

84 Replies 8 πŸ‘ 12 πŸ”₯

profile
@RedSunCap #droscrew
recently

cutting ZYME for 50% loss

108 Replies 12 πŸ‘ 10 πŸ”₯

Key Metrics

Market Cap

320.05 M

Beta

1.21

Avg. Volume

1.15 M

Shares Outstanding

57.77 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-03

Next Dividend Date

Company Information

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetricβ„’ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLinkβ„’ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

Website:

HQ: 540-1385 West 8Th Avenue Vancouver, V6H 3V9 British Columbia

Related News